Intra-Cellular Therapies (ITCI) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ITCI Intra-Cellular Therapies

Watchlist

86.590
+0.160+0.19%

Close Nov 27 16:00 ET

86.590
0.0000.00%

Post 16:00 ET

9.18BMarket Cap-99528P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)
TipRanks20:47 ET · Ratings
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
Seeking AlphaNov 26 14:01 ET
UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87
Moomoo NewsNov 19 13:31 ET · Ratings
Express News | Intra-Cellular Therapies Inc : UBS Raises Target Price to $87 From $79
ReutersNov 19 10:39 ET
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
GlobeNewswireNov 19 08:00 ET
US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16 02:13 ET

Comments

Tonyco

Oct 9 22:43

Columns Scribblings of a madman!

Ready for some research results?
Summary: XTNT is really undervalued and oversold. Also, ITCI, I guess. Not LLY though, fuck them.

Meltyy

Apr 1 02:47

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies (ITCI.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$Hutchmed (China) (HCM.US)$ Phase 3
$Viracta Therapeutics (VIRX.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Marinus Pharmaceuticals (MRNS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3...

Moomoo AI

Mar 27 10:03

Intra-Cellular Therapies is nearing breakeven, contingent on maintaining a 57% annual growth rate. Its lack of debt, unusual for a pharma company, reduces investment risk.

Market Sentiment Around Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Meltyy

Mar 21 21:48

Mental Health Biotech Catalyst Watchlist

$Vanda Pharmaceuticals (VNDA.US)$ PDUFA
$Intra-Cellular Therapies (ITCI.US)$ Phase 3
$Bristol-Myers Squibb (BMY.US)$ PDUFA
$Alzamend Neuro (ALZN.US)$ Phase 2
$Alzamend Neuro (ALZN.US)$ Phase 2a

Meltyy

Feb 21 22:05

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q1 2024...
$Pfizer (PFE.US)$ Phase 3
$Palatin Technologies (PTN.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ $Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

ITCI Intra-Cellular Therapies

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target